Notable Phase 2 (111In Ibritumomab Tiuxetan, 90Y ibritumomab tiuxetan, ASCT) Grade 3–4 toxicities included leukopenia, neutropenia, thrombocytopenia, nausea/vomiting, febrile neutropenia, anemia, headache, myalgia, elevated creatinine, elevated AST, elevated ALT, infection with neutropenia, and diarrhea. This evidence concerns the gene GPT and infection.